News


Neurological Sciences

New scientific publication in the journal Neurological Sciences: Transcutaneous supraorbital neurostimulation using the Cefaly device for the prevention of chronic migraine

May 2017

> Abstract

> read more


BMC Neurology 2017

New publication in the scientific journal BMC Neurology: Efficacy of the Cefaly device on refractory migraines

May 2017

> read more


Internal Medicine Review

New scientific publication in Internal Medicine Review: "Migraine treatment with external trigeminal nerve stimulation: current knowledge on mechanisms"

March 2017

> Abstract

> read more


Cefaly growth

Cefaly Technology starts the year with a 30% growth

March 2017

> read more (in French)


Launch Cefaly2 Bangladesh

Cefaly Technology signs a contract with Bangladesh

January 2017

> read more (in French)


Contrat in South Africa

Cefaly Technology signs a contract with South Africa

December 2016

> read more (in French)


Launch Cefaly2 Europe

Launch of Cefaly 2 in Europe

September 2016

> read more (in French)


Launch Cefaly2 USA

Launch of Cefaly 2 in the USA

July 2016

> read more


Contract in China

Migraine Medical Device, Cefaly, Shows Better Long-Term Patient Compliance than Migraine Medication

>> read more


Contract in China

Cefaly Technology signs a record-breaking contract in China

December 2015, Cefaly Technology signs a record-breaking contract of € 6.5 million in China with the Angenieux Trading Shanghai Co Ltd.

>> read more (in French)


Belgian Brain Council

The Belgian Brain Council announces the 2016 Cefaly Technology Award

Granting € 15,000, it will reward a specific research project in clinical and/or fundamental neuroscience which will contribute to increasing knowledge about the brain and its diseases or dysfunctions.

>> read more (in French)

Call for Applicants - Read more on www.rechercheneurologie.org


Study The Journal of Headache and Pain

New study finds Cefaly has very high efficacy for migraine prevention

Results from a new clinical trial, published in The Journal of Headache and Pain, confirm the FDA-approved device has 81% efficacy among migraine sufferers.
>> read more



New Study Shows CEFALY Activity on Head and Neck Muscles in Chronic Migraine Patients

June 2015: New Study Shows CEFALY Activity on Head and Neck Muscles in Chronic Migraine Patients.
>> read more


Communiqué Chine

Cefaly Technology signs an agreement protocol with the Hangzou Normal University

25th June 2015, Cefaly Technology and the Coma Science Group from the University of Liège sign an agreement protocol in Shangai with the Hangzou Normal University during the official state visit of King Philippe and Queen Mathilde to the People's Republic of China.

>> read more (in French)


Communiqué étude PET scan

Cefaly Technology presents data from a new PET scan trial at the International Headache Society Congress in Valencia, Spain

May 14-17, The new study shows Cefaly returns metabolism activity to brain areas in migraine patients

>> read more


Manager liégeois de l'année 2014

Pierre Rigaux voted ‘Manager liégeois de l'année 2014’

As part of the ‘Citoyen de l’Année 2014’ action, organised by the Sud Presse Group in collaboration with the Loterie nationale, RTC and RTBF (Vivacité) in the region of Liège, Mr Pierre Rigaux, CEO of Cefaly Technology, was attributed the award of ‘Manager liégeois de l'année 2014’ during a gala event held on February 3 at the Forum in Liège.


CT

10,000 U.S. Migraine patients who used FDA-Approved Cefaly device find relief

Early January 2015, Cefaly Technology is pleased to report that the Cefaly® sales have passed the 10,000 units mark. This symbolic milestone, illustrates that Cefaly® has indeed found a way to help migraineurs control, even eliminate, their migraines. The U.S. data of more than 10,000 patients shows more than a 94% success rate..."

> read more


CT

Migraine Prevention Device CEFALY® Opens U.S. Office for Faster Delivery, Quicker Relief

On December, Cefaly® has opened its first U.S. office in Darien, Connecticut. The new space will serve as the exclusive distributor of Cefaly® in the United States. The devices will ship from a contracted warehouse in Pennsylvania.

http://www.prnewswire.com/news-releases/migraine-prevention-device-cefaly-opens-us-office-for-faster-delivery-quicker-relief-300006103.htm


EY

Cefaly Techology voted ‘L’Entreprise Prometteuse de l’Année®

On October 14th CEFALY Technology received the ‘L’Entreprise Prometteuse de l’Année®’ award. The award is granted by EY advisory company with the support of BNP Paribas and L’Echo, and honours a young company in full expansion.

Entreprise Prometteuse de l’Année®

"By choosing CEFALY Technology from a group of remarkable and promising nominees, the ‘L’Entreprise Prometteuse de l’Année 2014®’ jury is honoring a company that has developed a very innovative product with great international potential. The company has a mature and experienced management team that in the future perhaps will guide the company to the distinction of ‘L'Entreprise the l'Année®’. This indeed is the jury’s wish for the company", has concluded Pierre Rion, jury chairman.

> Photos of the Award Ceremony


CT

Visit of Jean-Claude Marcourt, Vice-President of the Walloon Government

On April 23, Jean-Claude Marcourt, Vice-President of the Walloon Government and Minister in charge of the Economy, the SMEs, the Foreign Trade and the New Technologies, and Vice-President of the Wallonia-Brussels Federation and Minister in charge of Higher Education, came to the company's headquarter for a workshop on the development of the company's activities and on the significant growth of the exportation faced by the company.


CT

Launch of export to the USA

April 1st is the real start of the commercialization of the Cefaly in the United States. The publication in March by the FDA of a press release about the market authorisation of the Cefaly in the US has been covered by all important US media including CNN, Fox News, … This national diffusion has boosted significantly the Cefaly sales in the US. About one thousand orders were placed since the FDA publication of the market authorization of the Cefaly.


CT

FDA approval

The company received from the US Food and Drug Administration (FDA) on March 8, the authorization to market its medical device Cefaly in the United States. The Cefaly was already protected by a US patent covering not only its technology but also its method. This market authorization given by the FDA not only gives a recognition to the device quality and efficacy but also opens right away, and in a quasi–exclusive manner, the US market.


CT

Participation to the economic princely mission to Saudi Arabia and the Sultanate of Oman

From 14 to 20 March 2014, Cefaly Technology took part to the economic princely mission organized in Saudi Arabia and in the Sultanate of Oman. This mission, chaired by HRH Princess Astrid representing King Philippe, allowed to prolong the first contacts taken during the Arab Health Exhibition organized in january 2014 in Dubaï and, amongst others, to set up a collaboration agreement with an important Saudi distribution company.


Arab Health

Participation to Arab Health

As each year since about 5 years, Cefaly Technology was present begin of this year in Dubaï and took part from 27 to 30 January to the Arab Health Exhibition, the Middle-East's largest professional fair dedicated to health. About 125 000 professional visitors, distributors and Neurology specialists originating mainly from the Middle-East have had a chance to test the efficacy of the Cefaly on the space reserved to the company within the Belgian Pavilion. In-depth contacts have been established with the perspective of future distribution partnerships for the Cefaly in Middle-East and particularly in Saudi Arabia and in Oman.

English